Skip to Content

Join the 'Mantle Cell Lymphoma' group to help and get support from people like you.

Mantle Cell Lymphoma News

Get Active, Beat Lymphoma?

Posted 12 Dec 2017 by Drugs.com

TUESDAY, Dec. 12, 2017 – Physical activity appears to help people with lymphoma survive their disease. That finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection. "As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but ...

FDA Approves Calquence (acalabrutinib) for Adults with Mantle Cell Lymphoma

Posted 31 Oct 2017 by Drugs.com

October 31, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma is a particularly aggressive cancer,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of He ...

Calquence Approved for Mantle Cell Lymphoma

Posted 31 Oct 2017 by Drugs.com

TUESDAY, Oct. 31, 2017 – Calquence (acalabrutinib) has been approved by the U.S. Food and Drug Administration to treat adults with mantle cell lymphoma. Mantle cell is an aggressive, fast-growing non-Hodgkin lymphoma, a cancer of the lymph system. Though it represents only 3 percent to 10 percent of non-Hodgkin cases in the United States, the cancer usually has spread by the time it's detected, ...

Calquence Approved for Mantle Cell Lymphoma

Posted 31 Oct 2017 by Drugs.com

TUESDAY, Oct. 31, 2017 – Calquence (acalabrutinib) has been approved by the U.S. Food and Drug Administration to treat adults with mantle cell lymphoma. Mantle cell is an aggressive, fast-growing non-Hodgkin lymphoma, a cancer of the lymph system. Though it represents only 3 percent to 10 percent of non-Hodgkin cases in the United States, the cancer usually has spread by the time it's detected, ...

Adding Rituximab to Standard Care May Prolong Lymphoma Survival

Posted 28 Sep 2017 by Drugs.com

WEDNESDAY, Sept. 27, 2017 – Long-term treatment with the drug rituximab (Rituxan) may extend the lives of some patients with a rare form of blood cancer, a new clinical trial finds. The disease, known as mantle-cell lymphoma, is generally incurable. But various treatments can prolong people's lives. Some patients, for instance, are able to undergo chemotherapy to wipe out the cancer cells, ...

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study ...

Immune Therapy Makes Headway Against a Lymphoma

Posted 8 Sep 2016 by Drugs.com

THURSDAY, Sept. 8, 2016 – Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells are removed from the patient's bloodstream. Then they're genetically modified so they can detect and attack cancerous B-cells, another type of white ...

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is ...

Ask a Question

Further Information

Related Condition Support Groups

Non-Hodgkin's Lymphoma

Related Drug Support Groups

methotrexate, Rituxan, rituximab, Revlimid, Imbruvica, Cytoxan, cyclophosphamide, Velcade, ibrutinib, view more... doxorubicin, vincristine, cytarabine, lenalidomide, Neosar, bortezomib, Calquence, acalabrutinib, Cytoxan Lyophilized, mitoxantrone